-
Lepu Bio-PD-1 declared the second indication: MSI-H solid tumor
Time of Update: 2021-12-09
Author: ArmstrongOn October 26, 2021, the listing application of Lepu Bio's PD-1 monoclonal antibody Pritlizumab (HX008) for the treatment of MSI-H/dMMR solid tumors was accepted by NMPA, which is the second adaptation of the product declaration Disease .
-
Lepu Bio-Putlizumab plans to be included in the priority review for the treatment of MSI-H/dMMR advanced solid tumors
Time of Update: 2021-12-09
On October 28th, the CDE official website revealed that Lepu Biologic’s Pucotenlimab injection (pucotenlimab, HX008) is planned to be included in the priority review for the treatment of highly unstable microsatellites ( Patients with advanced solid tumors with MSI-H) or defective mismatch repair (dMMR) .
-
Clin Cancer Res: Anti-tumor activity and safety of PD-L1 antibody alone or in combination with TIM-3 antibody in MSI-H/dMMR advanced tumors
Time of Update: 2021-12-03
Recruited 18-year-old patients with advanced solid tumors who had not received anti-PD-1/PD-L1 treatment and had clear microsatellite instability-high/mismatch repair defects, and received LY3300054 as a single agent (single agent group, n=40) or LY3300054+LY3321367 (pre-treatment combination group, n=20) treatment; PD-1/PD-L1 inhibitor-resistant/refractory patients receive combined treatment (drug-resistant/refractory combination group, n =22) .
-
CheckMate 142 study nivolumumab + low-dose ipilimumab first-line treatment of MSI-H/dMMR
Time of Update: 2021-10-21
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can ad
-
Clin Cancer Res: Activity and safety of α-PD-L1 antibody ± α-TIM-3 antibody in the treatment of MSI-H/dMMR tumors
Time of Update: 2021-09-11
The incidence of treatment-related adverse events (TRAE) in the single-drug cohort, PD-1/PD-L1 inhibitor-initial combined cohort, and PD-1/PD-L1 inhibitor-resistant/refractory combined cohort were respectively 55.
3% (6 cases) treatment-related adverse events (TRAE) were in the single-drug cohort, PD-1/PD-L1 inhibitor-initial combined cohort and PD-1 /PD-L1 inhibitor resistance/refractory combined cohort incidence rates were 55.
-
by the National Food and Drug Administration for the treatment of MSI-H/dMMR solid tumors!
Time of Update: 2021-06-19
News on April 23, 2021 // --Henlius recently announced that its independently developed and innovative PD-1 inhibitor slulimumab (serplulimab, HLX10, recombinant humanized anti-PD-1 monoclonal antibody) injection has been treated with standard treatment The failed, unresectable or metastatic highly microsatellite unstable (MSI-H) solid tumor indication marketing registration application (NDA) was officially accepted by the National Medical Products Administration (NMPA), and it is planned to be included in the priority review process .
-
The 2021 edition of the NCCN Guidelines promotes the application status of MSI-H/dMMR. Has
Time of Update: 2021-04-21
Highly unstable microsatellite (MSI-H)/mismatch repair defect (dMMR) is currently one of the most important biomarkers for predicting the efficacy of immunotherapy, and has been applied to a variety of advanced entities including gastric cancer and colorectal cancer Screening of superior populations for tumor immunotherapy.
-
MSI-H/dMMR Advanced Solid Tumors: How do each PD-1/PD-L1 perform?
Time of Update: 2021-01-19
On November 16, 2020, Synaptic Pharmaceuticals announced a new drug listing application (KN035) for a recombinant humanized PD-L1 monometric antibody Nvolly monoantigen injection (KN035) in a strateg
-
China NMPA receives the NDA of Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors
Time of Update: 2021-01-15
Biopharmaceutical company TRACON announced today that China's State Drug Administration (NMPA) has accepted a new drug application (NDA) from Envafolimab (KN035) for the treatment of MSI-H/dMMR advanced solid tumors.
-
MSI-H/dMMR advanced solid tumors: how does each PD-1/PD-L1 perform?
Time of Update: 2021-01-09
In the past, anti-tumor drugs were often marketed to identify tumor types by source, such as for the treatment of "lung cancer," "kidney cancer," "breast cancer," "liver cancer" and so on. in the fie
-
Under-skin injection PD-L1 single anti-KN035 listing application was accepted by CDE! Treatment of MSI-H/dMMR solid tumors
Time of Update: 2021-01-04
("First Sound Pharmaceuticals") to restructure the humanized PD-L1 mono-domain antibody Nvolly monoanti-anti-injection (research and development code: KN035) The application for a biological product listing license (BLA) was accepted by the State Drug Administration (NMPA) on December 17, and the relevant adaptations include standard treatment for failed microsatellite instability (MSI-H)/mismatch repair functional defects (dMMR) advanced colorectal cancer, stomach cancer and other advanced solid tumors.
-
MSI-H/dMMR advanced solid tumors: how does each PD-1/PD-L1 perform?
Time of Update: 2020-11-26
On November 16, 2020, Synaptic Pharmaceuticals announced a new drug listing application (KN035) for a recombinant humanized PD-L1 monometric antibody Nvolly monoantigen injection (KN035) in a strategi
-
Domestic PD-L1 antibody! Cornerstone pharmaceutical cs1001 showed good antitumor activity and safety in MSI-H / dmmr solid tumor patients
Time of Update: 2019-09-24
September 24, 2019 / biogu BIOON / - cornerstone Pharmaceutical (Suzhou) Co., Ltd (hereinafter referred to as "cornerstone pharmaceutical") recently published in the form of oral report at the 22nd Na
